Visual acuity not maintained with anti-VEGF

A follow-up study was conducted to determine the long-term benefit and visual acuity outcomes of patients undergoing anti-VEGF treatments, such as Eyelea, Lucentis and Avastin. What researchers found was that visual gains were not maintained after 5 years of injections. Records of 647 patients with wet AMD were analyzed in the Comparison of Age-Related Macular […]

Avastin and Lucentis both pose same risk of infection

Doctors who were quick to come the defense of using the much more costly Lucentis to treat macular degeneration rather than its cheaper counterpart Avastin tried to argue that Lucentis had a lower risk of infection. However, a recent study conducted by the University of Pennsylvania found that argument is not true. In the study, more […]

Avastin more effective for diabetic macular edema

A recent study did a comparison of the three top drugs used to treat diabetic macular edema. Researchers took a look at Avastin, Eylea and Lucentis and while all three drugs were equally effective in improving vision in patients who had slight vision impairment, Eylea was found to be more effective in treating patients with […]

Does cost go into macular degeneration prescription decisions?

When it comes to treating the wet form of macular degeneration, there are two drugs that doctors typically consider and while the drugs are equally effective, the cost of each is dramatically different. Researchers decided to examine whether the cost difference between these two had significant bearing upon which drug a doctor prescribed. Ranibizumab was […]

UK Teaching hospitals using new wet AMD treatment

Some wet AMD patients in the United Kingdom are now receiving a new, non-invasive treatment for their disease. The new treatment known as Oraya Therapy™ is being used by eye specialists at the Sheffield’s Royal Hallamshire Hospital. This new therapy is painless and delivers highly targeted, low-energy X-rays to the eye. The amount of radiation […]

Single shot gene therapy could benefit wet AMD patients

Researchers at the Lions Eye Institute in Perth, Western Australia have created a new gene therapy that could potentially replace invasive monthly injections, which are the current method of treating the wet form of macular degeneration. A single injection carries a benign, modified virus which has a gene that creates a supply of a protein […]

Time-release coating developed to keep AMD drug in eye longer

A new drug-delivery system developed by a team of biomedical engineers at Johns Hopkins will enable a new wet macular degeneration drug to stay in the eye longer meaning fewer injections. The research team tested their new drug and its time-release coating in mice that had similar eye abnormalities as are found in people with […]

Eylea injections effective when other treatments for wet AMD have failed

A recent study conducted at the University of Iowa revealed that macular degeneration patients benefited from bimonthly injections of Eylea when monthly injections of Avastin or Lucentis failed. The injections are used for patients dealing with the wet form of macular degneration. Thirty-one patients in the study saw a reduction in fluid within their eyes […]

Beta-blockers may lessen frequency of injections

Patients being treated for wet macular degeneration with intravitreal injections of Avastin may require fewer injections if also treated with systemic beta-blockers. The recent study which involved 46 patients who had wet macular degeneration revealed that those patients who were also being treated with beta-blockers required on average 5.2 injections compared to 7.9 in those […]

FDA issues warning about Avastin Injections

In the aftermath of several recent meningitis deaths, the FDA is warning patients whose eyes were injected with Avastin formulated by New England Compounding Center about the risk of fungal infection to their eye. Avastin is a common drug used to treat wet macular degeneration. Read more here: http://www.fda.gov/Drugs/DrugSafety/ucm322734.htm